Table 2.
The cumulative risk of clinical outcomes according to antithrombotic therapy.
| Outcome | Warfarin | DOAC | *HR (95% CI) | p-Value |
|---|---|---|---|---|
| Event (IR) | Event (IR) | |||
| Recurrent stroke | 2294 (4.9) | 1184 (4.2) | 0.67 (0.62–0.72) | <0.001 |
| Major bleeding | 1263 (2.6) | 633 (2.2) | 0.73 (0.66–0.80) | <0.001 |
| Composite outcome (Recurrent stroke + major bleeding) | 3387 (7.4) | 1765 (6.4) | 0.69 (0.65–0.73) | <0.001 |
| Fatal recurrent stroke | 501 (1.0) | 307 (1.1) | 0.69 (0.59–0.79) | <0.001 |
| Fatal major bleeding | 188 (0.4) | 60 (0.2) | 0.50 (0.37–0.68) | <0.001 |
| Fatal composite outcome | 684 (1.4) | 366 (1.3) | 0.65 (0.57–0.74) | <0.001 |
| All-cause death | 3169 (6.4) | 2092 (7.4) | 0.84 (0.80–0.89) | <0.001 |
* Inverse probability of treatment weighting (IPTW) adjustment. Abbreviation: CI, confidence interval; DOAC, direct oral anticoagulant; HR, hazard ratio; IR, incidence rate.